Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 1,440,000 shares, a drop of 36.3% from the September 30th total of 2,260,000 shares. Based on an average trading volume of 196,100 shares, the short-interest ratio is currently 7.3 days. Currently, 19.0% of the shares of the company are sold short. Currently, 19.0% of the shares of the company are sold short. Based on an average trading volume of 196,100 shares, the short-interest ratio is currently 7.3 days.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $45,000. XTX Topco Ltd acquired a new stake in Karyopharm Therapeutics during the 2nd quarter worth about $56,000. Bridgeway Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the second quarter valued at about $163,000. Silverback Asset Management LLC lifted its stake in Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after buying an additional 20,000 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Karyopharm Therapeutics in the first quarter worth about $523,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Performance

Shares of NASDAQ:KPTI traded up $0.27 on Monday, hitting $6.07. The company’s stock had a trading volume of 198,181 shares, compared to its average volume of 321,605. The company has a market capitalization of $52.63 million, a price-to-earnings ratio of -0.42 and a beta of 0.35. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $14.24. The stock’s 50-day moving average is $6.36 and its two-hundred day moving average is $5.40.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Monday, August 11th. The company reported ($4.32) earnings per share for the quarter, missing the consensus estimate of ($3.80) by ($0.52). The company had revenue of $37.93 million for the quarter, compared to analyst estimates of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. Equities analysts expect that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on KPTI. Robert W. Baird dropped their price target on Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, October 9th. Piper Sandler restated an “overweight” rating and set a $12.00 price objective (down from $15.00) on shares of Karyopharm Therapeutics in a research note on Thursday, October 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright raised shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a report on Monday, October 13th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.20.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).